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VIII. ABSTRAK 
 
Pendahuluan 
Diabetes jenis 2 (T2DM) sekarang merangkumi 90% dari semua jenis diabetes dan 80% 
kematian di dalam kumpulan ini adalah berkaitan dengan penyakit kardiovaskular. Risiko 
kematian akibat penyakit kardiovaskular di kalangan pengidap Gangguan Tolerans Glukosa 
(IGT) adalah lebih tinggi berbanding mereka yang paras glukosa normal. Perubahan patologi 
pada salurdarah bermula bebarapa tahun sebelum diabetes jenis 2 dikesan. 
 
Objektif Kajian 
Objektif Kajian ini ialah (i) untuk mengkaji epidemiologi klinikal  vaskulopati pra klinikal 
pesakit T2DM dan Gangguan Tolerans Glukosa ( IGT ) yang baru dikenalpasti dan belum 
dirawat  serta anak-anak mereka yang normoglisemia (Kajian 1), (ii) untuk mengkaji sama 
ada intervensi farmakologi menggunakan thiazolidinedione dan perencat enzim penukar 
angiotensin  ( ACE inhibitor ) mampu merubah vaskulopati praklinikal di kalangan pesakit 
T2DM dan IGT yang baru didiagnosa  (Kajian 2).  
 
Metodologi 
Saringan awal terhadap 1,620 orang telah dijalankan di mana 644  telah memenuhi syarat 
kajian. Mereka menjalani Ujian Tolerans Glucosa secara oral (OGTT) dan didapati  70 
(10.87%) mengidap T2DM dan 66 (10.25%) IGT. Bagi kajian 1 ( bahagian 1), 30 T2DM dan 
30 IGT telah dipilih dan dipadankan dari segi jantina dan umur dengan 30 orang yang paras 
gula normal sebagai kawalan. Data mengenai hemodinamik serta “pulse wave velocity” 
(PWV) dan ‘Augmentation Index” (AI) telah diukur.  Kajian 1 (bahagian 2) melibatkan 30 
 xxiv
orang yang paras glukosa normal terdiri dari anak-anak pesakit T2DM dan 30 anak-anak 
pesakit IGT dibandingkan dengan 30 orang anak-anak dari keluarga yang paras glukosa 
normal. Data mengenai hemodinamik, “pulse wave velocity” (PWV) dan ‘Augmentation 
Index” (AI) juga diukur. Bagi Kajian 2 seramai 33 orang T2DM dan 33 IGT yang 
dipadankan mengikut jantina dan umur telah dirawat dengan menggunakan sama ada 
rosiglitazone, ramipril atau plasebo selama satu tahun. Data mengenai hemodinamik telah 
diukur pada tiga fasa rawatan (bulan 1, 7, 12) manakala PWV dan AI diukur sepanjang 
tempoh rawatan  [bulan 1 (minggu 1, minggu 2, minggu 4), 3, 5, 7, 9, 11 dan 12].  
 
Keputusan 
Bagi Kajian 1 ( bahagian 1), PWV pesakit T2DM lebih tinggi secara bermakna (10.37+2.6 vs 
8.70+1.3m/s; p =0.035), dan PWV pesakit IGT melebihi secara sederhana (9.54+1.6 vs 
8.70+1.3m/s, p=0.078) berbanding mereka yang paras glukosa normal. Indeks Augmentasi 
(AI) pesakit T2DM melebihi secara sederhana (134.53+17.3 vs 129.17+11.2%, p=0.055) dan 
pesakit IGT (132.02+16.11 vs 129.17+11.2%, p=0.059) berbanding mereka yang paras 
glukosa normal. 
 
Di dalam Kajian 1 ( bahagian 2), anak-anak pesakit T2DM dan IGT menunjukkan AI yang 
lebih tinggi secara bermakna berbanding dengan kawalan (105.62+14.2 vs 96.42+7.7, 
p=0.001; 104.98+11.1 vs 96.42+7.7, p=0.004). PWV anak-anak pesakit T2DM juga lebih 
tinggi secara bermakna berbanding dengan kawalan (6.94+0.9 vs 6.33+0.7 m/s, p=0.010). 
Anak-anak T2DM juga menunjukkan PWV yang lebih tinggi secara bermakna berbanding 
dengan anak-anak IGT (6.94+0.9 vs 6.43+1.1, p=0.021). 
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Bagi Kajian 2, rosiglitazone menunjukkan penurunan PWV (p=0.039) dan AI (p=0.031) 
yang bermakna di kalangan pesakit IGT. Ramipril juga menunjukkan penurunan AI 
(p=0.025) berbanding plasebo semasa rawatan selama 12 bulan. Rosiglitazone dan ramipril 
tidak menunjukkan penurunan PWV (p=0.962 dan p=1.000) dan AI (p=0.897 dan p=0.677) 
yang bermakna di kalangan pesakit T2DM berbanding plasebo sepanjang tempoh rawatan. 
 
Kesimpulan 
Pesakit T2DM yang baru didiagnosa menunjukkan menifestasi pra klinikal awal penyakit 
vaskular makro seperti yang ditunjukkan oleh PWV yang tinggi. Anak-anak pesakit T2DM 
yang normal paras glukosa juga menunjukkan  vaskulopati praklinikal di mana PWV dan AI 
adalah tinggi. Anak-anak pesakit IGT juga menunjukkan  pembuluh darah  yang tidak 
normal di mana AI juga tinggi. Rosiglitazone menukarkan keadaan  vaskulopati praklinikal 
di kalangan IGT sebagaimana ditunjukkan oleh penurunan PWV dan AI semasa rawatan 
selama satu tahun. Selepas satu tahun rawatan  ramipril , didapati ketegangan salurdarah 
besar di kalangan pesakit IGT berkurangan sebagaimana ditunjukkan oleh penurunan AI. 
 
 
 xxvi
IX. ABSTRACT 
 
 
Introduction 
Type 2 diabetes (T2DM) now accounts for 90% of all diabetes and 80% of deaths in this 
group are cardiovascular related. The risk of cardiovascular mortality is also substantially 
higher in individuals with impaired glucose tolerance (IGT) than in those with normal 
glucose levels and the pathological changes in vascular function begin many years before the 
diagnosis of overt T2DM.  
 
Aim of studies 
The aims of this thesis are (i) to investigate clinical epidemiology of pre-clinical 
vasculopathy in newly-diagnosed, untreated T2DM and IGT patients and their 
normoglycaemic offspring (Study 1), and (ii) to examine whether pharmacological 
interventions with thiazolidinedione and angiotensin converting enzyme (ACE) inhibitors 
can reverse pre-clinical vasculopathy in newly diagnosed diabetic and IGT individuals 
(Study 2). 
 
Methodology 
Initial screening of 1620 subjects was conducted of which, 644 met study criteria. They had 
oral glucose tolerance test (OGTT) – 70 (10.87%) were T2DM and 66 (10.25%) IGT 
individuals. For Study 1 (Part 1), the first 30 T2DM and 30 IGT patients were recruited and 
compared with age- and sex-matched 30 normoglycaemic controls. Haemodynamic 
variables, pulse wave velocity (PWV) and augmentation index (AI) were measured. Study-1 
(Part-2) involved 30 healthy normoglycaemic offspring of T2DM and 30 healthy 
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normoglycaemic offspring of IGT patients, compared with 30 age- and sex-matched healthy 
offspring of normoglycaemic parents. Haemodynamic variables, PWV and AI were 
measured. For Study-2, age- and sex-matched 33 T2DM and 33 IGT patients were enrolled, 
comparing one-year treatment with rosiglitazone, ramipril and placebo. Haemodynamic 
variables were measured at three treatment phases (1st, 7th and 12th month) and PWV and AI 
were measured through out the treatment period [1st (week 1, week 2, week 4), 3rd, 5th, 7th, 
9th, 11th, and 12th month]. 
 
Result 
In Study-1 (Part-1), PWV was significantly higher in T2DM patients (10.37+2.64vs. 
8.70+1.29m/s; p=0.035) and was of borderline significant in IGT subjects 
(9.54+1.56vs.8.70+1.29m/s, p=0.078) compared to normoglycaemic individuals. 
Augmentation index was higher of borderline significant in T2DM (134.53+17.32 vs. 
129.17+ 11.18 %, p=0.055) and IGT patients (132.02+16.11 vs. 129.17+ 11.18 %, p=0.059) 
compared to normoglycaemic individuals. 
 
In Study 1 (Part-2), offspring of T2DM and IGT patients demonstrated significantly higher 
AI compared to controls (105.62+14.2 vs. 96.42+7.7, p=0.001; 104.98+11.1 vs. 
96.42+7.7%, p=0.004 respectively). Significantly higher PWV was noted in offspring of 
T2DM compared to offspring of normoglycaemic parents (6.94+0.9 vs.6.33+0.7m/s, 
p=0.010). It was also found to be significantly higher in the offspring of T2DM compared to 
that of IGT (6.94+0.9 vs. 6.43+1.1, p=0.021). 
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In Study-2, rosiglitazone showed a significant reduction in PWV (p=0.039) and AI 
(p=0.031) and ramipril demonstrated a significant reduction of AI (p=0.025) in IGT patients 
in comparison to placebo on the 12th month of treatment. With rosiglitazone and ramipril, no 
significant difference was observed in PWV (p=0.962 and p=1.000 respectively) and AI 
(p=0.897 and p=0.677 respectively) in T2DM patients in comparison to placebo during 
overall treatment period. 
 
Conclusion 
Newly diagnosed untreated T2DM patients demonstrated early preclinical manifestations of 
macrovascular diseases as shown by significantly increased PWV.  Normoglycaemic healthy 
offspring of T2DM patients had demonstrable pre-clinical vasculopathy as assessed by 
significantly increased PWV and AI. Normoglycaemic healthy offspring of IGT individuals 
had also large artery abnormalities as shown by significantly increased AI. Rosiglitazone 
significantly reverses pre-clinical vasculopathy in IGT patients as evident by significant 
decrease in PWV and AI after one-year treatment. After one-year of ramipril treatment, 
reduction of large artery stiffness was also observed among IGT patients as shown by 
significant decrease in AI. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Diabetes and pre-diabetic vascular diseases: An overview  
Diabetes mellitus is a metabolic disorder characterised by chronic hyperglycaemia 
with disturbances of carbohydrate, fat and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both (WHO, 1999). Diabetes is the 
fourth or fifth leading cause of death in most developed countries and there is 
substantial evidence that it is epidemic in many developing and newly industrialised 
nations (IDF, 2003).  Patients with type 2 diabetes mellitus (T2DM) have a risk of 
death from cardiovascular (CV) causes, which is two to six times than that of 
persons without diabetes (Gæde et al., 2003). The CV events associated with T2DM 
and the high incidence of other macrovascular complications, such as strokes and 
amputations, are a major cause of illness and an enormous economic burden 
(O'Brien et al., 2003). 
 
1.2 Diabetes: Definition, diagnosis and classification 
Diabetes is diagnosed if the (venous) fasting plasma glucose (FPG) value is > 7.0 
mmol/L (126 mg/dl), or if the casual plasma glucose value is > 11.1 mmol/L (200 
mg/dl), or if the plasma glucose value 2 hours after a 75g oral load of glucose > 
11.1 mmol/L (200 mg/dl) (Table 1.1). Impaired glucose regulation (Impaired 
glucose tolerance and impaired fasting glycaemia) refers to a metabolic state 
intermediate between normal glucose homeostasis and diabetes (WHO, 1999).  
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Table 1.1: Biochemical criteria (venous plasma) for the diagnosis of diabetes, 
impaired glucose tolerance and fasting glucose or impaired fasting 
glucose 
 
 Glucose concentration mmol/L (mg/dl)  
(Venous plasma) 
 
Diabetes mellitus: 
   
 Fasting and/or  
 
   2-hrs post glucose load 
 
 
 
  
   7.0 ( 126) 
 
   11.1 ( 200) 
 
 
Impaired glucose tolerance (IGT) 
 
   Fasting 
 
   and 2-hrs post glucose load 
 
 
 
 
 <   7.0 (< 126) 
 
    7.8 ( 140) and  < 11.1 (<200) 
 
 
Impaired fasting Glycaemia  
or impaired glucose (IFG) 
 
   Fasting  
 
   and 2-hrs post glucose load 
 
 
 
 
 
  6.1 ( 110) and <7.0 (<126) 
  
<   7.8 (<140) 
 
Source: (WHO, 1999; Unwin et al., 2002) 
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Impaired glucose tolerance (IGT) is categorised as a stage in the natural history of 
disordered carbohydrate metabolism. Impaired fasting glycaemia (IFG) refers to 
fasting glucose concentrations, which are lower than those required to diagnose 
diabetes but higher than the ‘normal’ reference range. Impaired fasting glycaemia 
and IGT are not interchangeable and represent different abnormalities of glucose 
regulation, one in the fasting state and one post–prandial; however, both are risk 
categories for the future development of T2DM and cardiovascular disease (CVD).  
 
 
1.2.1 Type 1 Diabetes  
Type 1 diabetes results from cellular-mediated autoimmune destruction of 
pancreatic islet beta-cells causing the loss of insulin production (Atkinson & 
Maclaren, 1994). It ranks as the most common chronic childhood disease in 
developed nations (LaPorte et al., 1995) but occurs at all ages (Molbak et al., 
1994) and the clinical presentation can vary with age (Gleichmann et al., 1984; 
Groop et al., 1986). The global incidence of type 1 diabetes in children and 
adolescents is increasing with an estimated overall annual increase of around 3% 
(Onkamo et al., 1999; EURODIAB ACE Study Group, 2000; Green & Patterson 
2001). It is estimated that on an annual basis some 65,000 children aged less than 15 
years develop the disease worldwide. Of the estimated total of approximately 
430,000 prevalent cases of type 1 diabetes in childhood, more than a quarter come 
from the South-East Asian (SEA) Region, and more than a fifth from the European 
(EUR) Region. Despite having the largest childhood population, the Western Pacific 
(WP) Region has the lowest number of type 1 cases. 
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The predominant cause of hyperglycaemia in type 1 diabetes is the autoimmune 
destruction of the beta cells, which leads to absolute dependence on insulin 
treatment and a high rate of complications typically occurring at relatively young 
ages. Type 1 diabetes, therefore, places a particularly heavy burden on the 
individual, the family and the health services. 
 
1.2.2 Type 2 Diabetes (T2DM) 
Type 2 diabetes is characterized by insulin resistance and relative insulin deficiency, 
either of which may be present at the time that diabetes becomes clinically manifest 
(Reaven et al., 1976; Tuomilehto et al., 2001). The specific reasons for the 
development of these abnormalities are not yet known. The diagnosis of T2DM 
usually occurs after the age of 40 years although the age of onset is often a decade 
earlier in populations with high diabetes prevalence (Zimmet et al., 1990b). People 
with T2DM may not show any symptoms for many years and the diagnosis is often 
made from associated complications or incidentally through an abnormal blood or 
urine glucose test. 
 
Type 2 diabetes is often, but not always, associated with obesity, which itself can 
cause insulin resistance and lead to elevated blood sugar levels. It is strongly 
familial, but major susceptibility genes have not yet been identified. In contrast to 
type 1 diabetes, persons with T2DM are not dependent on exogenous insulin and are 
not ketosis-prone, but may require insulin for control of hyperglycaemia if this is 
not achieved with diet alone or with oral hypoglycaemic agents.  
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1.2.3 Impaired Glucose Tolerance (IGT) 
Impaired glucose tolerance is an intermediate category between normal glucose 
tolerance and overt diabetes (Harris, 1989; WHO, 1994). Several previous 
prospective studies have shown that subjects with IGT are at high risk of 
progression to T2DM (King et al., 1984; Saad et al., 1988; Schranz, 1989; Motala et 
al., 1993; Nijpels et al., 1996). And it is estimated that about 40-70% of people with 
IGT would progress to T2DM (Alberti, 1998; IDF, 2003). People with IGT are 
known to be at significantly increased risk of CVD than those with normal glucose 
levels and the pathological changes in vascular function begin many years before 
the diagnosis of overt T2DM (Tominaga et al., 1999). The Whitehall study (Fuller 
et al., 1980) and the Bedford survey (Jarrett et al., 1982) mentioned that IGT is 
associated with increased risk of macrovascular disease. The DECODE (Diabetes 
Epidemiology: Collaborative analysis of Diagnostic criteria in Europe) study (2003) 
found that people with IGT were 50% more likely to die of CV complications 
during follow-up than people with normal blood glucose control. The most alarming 
conclusion of the study was that as there were four times as many people with IGT 
as with diabetes, there were more premature deaths attributable to IGT than to 
diabetes.  
 
1.3 Global diabetes catastrophe 
Diabetes is a global health problem and has been described as the epidemic of the 
21st century (Ramachandran & Snehalatha, 1999). It accounts for about 85% to 
95% of all diabetes in developed countries, with even higher percentage in 
developing countries (IDF, 2003). The number of people with diabetes is escalating 
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both in the developed and developing countries. Diabetes currently affects 5% of 
the world’s population (Marso, 2003) and its prevalence is doubling every 
generation (Gerdes, 2003).  
 
1.3.1 Global estimates of diabetes 
In 1994, the International Diabetes Federation (IDF, 1994) estimated that over 100 
million people worldwide had diabetes. The recent statistics of the International 
Diabetes Federation (IDF, 2003) are alarming – approximately 194 million people 
worldwide have diabetes.  This estimate is expected to increase to some 333 
million, or 6.3% of the adult population, by 2025 and 366 million by 2030 (IDF, 
2003). Table 1.2 shows the worldwide prevalence of diabetes and IGT.  
 
The number of people with diabetes in Malaysia is increasing alarmingly 
(NDS/MOH, 2003) (Table 1.3), as the country is ‘seeing a major shift in lifestyles 
and longevity of the population’ (Zaini, 2000). In the National Health and Morbidity 
Survey I the prevalence of T2DM and IGT were estimated to be 6.3% and 4.8% 
respectively (NHMSI, 1986). However, the second National Health and Morbidity 
Survey showed that the national prevalence is estimated to be 8.3% with 7% of 
adult population had blood glucose in the diabetic range and 5% in the IGT 
(NHMSII, 1996). The survey revealed variations in the observed prevalence by 
states and ethnicity. Highest observed prevalence occurred in the more developed 
states and in Indians ethnic.  
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 Table 1.2: Diabetes and IGT: Prevalence and projections 
All diabetes and IGT 2003 2025 
Total world population (billions) 6.3 8.0 
Adult population (millions) (20-79 years) 3.8 5.3 
Number of people with diabetes (millions) (20-79 
years) 
194 333 
World diabetes prevalence (%)(20-79 years) 5.1 6.3 
Number of people with IGT (millions) (20-79 years) 314 472 
IGT prevalence 8.2 9.0 
Source: IDF (2003) 
 
 
 
Table 1.3: Projection of diabetes in Malaysia  
 
Burden of 
diseases 
1996 
NHMSII 
2002 2006 2010 2020 
 
Diabetes 
Mellitus 
 
 
608,000 
(8.3%) 
 
836,200 
(9.5%) 
 
983,650 
(10.3%) 
 
1,109,200 
(11.1%) 
 
1,558,660 
(13.1%) 
 
Note: Based on NHMSII 1996. Prevalence rate increase proportionately. 
 
Source: NDS/MOH (2003) 
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The prevalence and projections of T2DM and IGT in Malaysia, according to 
Diabetes Atlas (IDF, 2003), are shown in Table 1.4. Diabetes prevalence and risk 
factors reported in national surveys are also shown in Table 1.5. A study conducted 
in Kelantan (n=2508; ≥30 years) found prevalence of diabetes at 10.5% and IGT at 
16.5% (Mafauzy et al., 1999). Khebir et al. (1996) studied the changing prevalence 
of T2DM amongst rural Malays in Kuala Selangor and represented a marked 
increment of 212.8 per cent over a 10-year period (1984-1994). Statistics from the 
Ministry of Health (MOH) records also showed increased number of admissions 
and deaths in government hospitals for diabetes (NDS/MOH, 2003) (Figure 1.1). 
Admission increased from 19,629 cases in 1991 to 30,661 cases in 2001, an increase 
of 56% over a span of 10 years and mortality also increased from 254 deaths in 
1991 to 380 deaths in 2001, which is an increase of 50%.  
 
1.4 Type 2 Diabetes and cardiovascular disease: Double jeopardy 
Cardiovascular disease is the major cause of morbidity and mortality in people with 
T2DM (Stemmer, 1997; Ness et al., 1999) and coronary heart disease is the most 
common cause of death. It is estimated that up to 80% of the 200 million people 
with diabetes globally will die of CVD (UKPDS, 1996; IDF, 2003). Multiple 
modifiable risk factors for late complications in patients with T2DM, including 
hyperglycaemia, hypertension, and dyslipidaemia, increase the risk of a poor 
outcome (Stamler et al., 1993). Up to 70% of people with T2DM have raised BP 
and over 70% have raised cholesterol levels. Management of blood lipid, 
hypertension and blood glucose levels can contribute to the reduction in CV risk in 
people with T2DM (Table 1.6). 
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Table 1.4: Diabetes and IGT: Prevalence and projections in Malaysia 
 2003 2025 
Population (20-79) (million) 13,280 21,032 
Diabetes prevalence (%) 9.4 12.4 
IGT prevalence (%) 17.7 18.4 
Rural (million) 323.5 449.0 
Urban (million) 928.1 2153.1 
   
 Diabetes IGT Diabetes IGT 
Male  527.3 1173.7 1088.4 1933.5 
Female 724.3 1174.3 1513.7 1926.4 
20-39 years 134.6 919.9 205.9 1299.5 
40-59 years 688.4 1131.3 1207.1 1802.8 
60-79 years 428.6 296.9 1189.1 757.7 
Total 1251.6 2348.0 2602.1 3860.6 
Source: IDF (2003). 
 
 
Table 1.5: Diabetes prevalence and risk factors in Malaysia 
 1986 
NHMS1 
1996 
NHMS2 
Diabetes Prevalence 6.3% 8.3% 
Impaired Glucose Tolerance 4.8% 4.3% 
Prevalence of undiagnosed 
diabetes 
1.8% 2.5% 
Hypertension  29.9% 
Smoking  24.8% 
Overweight  21%. 
Adequate physical activity  11.6%. 
Source: NDS/MOH (2003). 
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Figure 1.1: Admission and death of diabetes cases in Govt. Hospitals (1998-
2003) 
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Source: NDS/MOH (2003). 
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Table 1.6: Reduction of risk of complications in people with T2DM 
 
Strategy Complications Reduction of 
complications 
Lipid control Coronary heart disease mortality 36%1 
Major coronary heart disease event 55%1 
 Any atherosclerosis event 37%1 
 Cerebrovascular disease event 62%1 
Blood pressure control Cardiovascular disease 51%2 
Heart failure 56%3 
 Stroke 44%3 
 Diabetes related deaths 32%3 
Blood glucose control Heart attack 37%3 
  
 Source:  1The 4S Study (Pyörälä et al., 1997) 
 2Hypertension Optimal Treatment (HOT) Randomised Trial   (Hansson et 
al., 1998) 
  3UKPDS Group (1996). 
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1.5 Cardiovascular risk factors in diabetic patients 
Among the traditional risk factors, smoking, hypercholesterolemia, 
hypertriglyceridaemia, fasting plasma glucose concentration and hypertension are 
probably the most important in diabetic patients. However, several factors, unique 
to diabetes, may confound the impact of these traditional factors and independently 
influence the atherosclerotic process, thereby increasing the morbidity and mortality 
in this group. These additional risk factors include chronic inflammation (C-reactive 
protein and interlukin-6), endothelial dysfunction, advance glycated end products 
(AGEs), plasminogen activator 1, fibrinogen, and genetic susceptibility. Risk 
factors and possible mechanisms of the excess risk of CVD in T2DM are shown in 
Table 1.7. 
 
Serum total cholesterol is a powerful predictor of ischemic heart disease morbidity 
and mortality in both diabetics and non-diabetics (Pyörälä et al., 1997). Besides 
total cholesterol, elevated triglycerides, increased low-density lipoprotein (LDL) 
cholesterol, and decreased high-density lipoprotein (HDL) cholesterol have also 
been shown to independently increase CV mortality in diabetic patients (Resnick & 
Howard, 2002). The Scandinavian Simvastatin Survival Study (Pyörälä et al., 1997) 
found that lowering cholesterol with HMG-CoA reductase inhibitors reduced the 
risk of major macrovascular events in patients with diabetes. Similarly, subgroup 
analysis of the Helsinki Heart Study, a 5-year ischemic heart disease primary 
prevention trial using gemfibrozil, provided additional evidence for the potential 
benefit of lipid-lowering agents for both non-diabetics and diabetics (Koskinen et 
al., 1992). 
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Table 1.7: Risk factors and possible mechanisms of the excess risk of CVD in  
                              T2DM 
 
Risk factors Possible mechanisms 
Hyperglycaemia Glycation/oxidation – lipoproteins;  
vessel wall matrix/collagen  
Increased protein kinase C – altered growth 
factors permeability and other vascular changes 
Hyperinsulinaemia and  
Insulin resistance 
Increased vascular matrix;  
Proliferation of arterial smooth muscle; 
Increased plasminogen-activator inhibitor-1 
concentrations; and increased dense LDL-
cholesterol concentration. 
Dyslipidaemia 
   High triglyceride concentration 
   Low serum HDL cholesterol 
   Small dense LDL cholesterol 
 
Lowers serum HDL cholesterol 
Atherogenesis 
Atherogenesis 
Increased central adiposity Insulin resistance; dyslipidaemia 
Increased plasminogen-activator 
inhibitor-1 
Decreases fibrinolysis 
Increased platelet aggregation/ 
adhesiveness 
Increases thrombosis 
Increased fibrinogen 
concentrations 
Thrombogenesis, atherogenesis 
 
Increased plasma oxidative state Endothelial damage; lipoprotein oxidation/ 
atherogenesis 
Renal dysfunction Atherogenesis, hypertension, oxidation 
Cardiovascular autonomic 
neuropathy 
Sudden death 
Abnormal vascular reactivity Vasoconstriction, ischaemia, hypertension 
Source: Nathan et al., 1997. 
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There is considerable debate concerning appropriate target levels for LDL lowering 
among diabetics (as well as non-diabetics). The National Cholesterol Education 
Program ATP III (NCEP Expert Panel, 2001) and American Diabetes Association 
guidelines indicate a goal of 100 mg/dl (2.6mmol/L) for individuals with diabetes 
because of their known high risk for CVD and tendency to have multiple risk 
factors. High LDL levels in diabetic patients are thought to be particularly 
atherogenic because of altered composition, glycation, and susceptibility to 
oxidation. However, more recent study suggested that an even lower level 
(<2mmol/L) confers better benefits (Colhoun et al., 2004). Obesity and central 
obesity are important contributors to the insulin resistance syndrome and predictors 
of coronary heart disease in non-diabetic individuals. According to several studies, 
they are not independently associated with coronary heart disease or other CV 
complications in patients with T2DM (Turner et al., 1998). Abnormal lipids, 
smoking, hypertension, abdominal obesity, psychosocial factors, less consumption 
of fruits, vegetables, more alcohol intake and sedentary life style all these are 
account for most of the risk of CV complication (Yusuf et al., 2004). Hypertension 
develops early in the course of the disease the prevalence is twice as high in patients 
with IGT as compared to normal controls. The association of hypertension with 
T2DM is ominous; mortality is increased by a factor of 4 to 7 in patients with 
T2DM and hypertension when compared to normotensive non-diabetic matched 
controls (The Hypertension in Diabetes Study Group, 1993).  
 
The UKPDS clearly demonstrated the link between hypertension and the high risk 
for CV complications in T2DM patients (Adler et al., 2000). The 10/5mmHg 
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difference in BP was associated with a 15% decrease in CVD, a 32% decrease in 
death due to diabetes, and a 44% reduction in the incidence of cerebrovascular 
attack. Although the optimum target BP for hypertensive with diabetes has not yet 
been determined with certainty, completed trials indicated that reducing systolic 
blood pressure (SBP) to at least 130 mmHg provides substantial reduction in both 
macro- and microvascular disease progression. Clinical trials have also 
demonstrated that treatment of BP even in the so-called normotensive range of 
T2DM is associated with prevention of BP elevation and increased urinary protein 
excretion, and would likely reduce the risk of CVD and the progression of renal 
disease (Viberti et al., 1994). The HOT study (Hansson et al., 1998) showed that 
optimum of diastolic blood pressure (DBP) for diabetic patients is <80mmHg. The 
ABCD-2 study (Schrier et al., 2002) showed that <130/80 mmHg is the optimum 
BP to reduce CV events. 
 
Researchers are already beginning to focus on the involvement of other non-
traditional, or diabetic-specific, risk factors in the development of CVD in diabetic 
patients. It has been proposed that markers of inflammation – such as interleukin-6 
(IL-6), C-reactive protein (CRP) – are part of a complex of pro-CVD risk factors 
characterising the insulin resistance syndrome. These markers contribute to CVD 
risk independently of established metabolic abnormalities commonly observed in 
insulin resistance. Studies have shown that T2DM patients with an elevated CRP 
have a high risk for coronary heart disease and an up to 8.5-fold increase in 
morbidity and mortality (Mojiminiyi et al., 2002).  
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Cardiovascular risk factors are found to be prevalent among normal population and 
T2DM patients in Malaysia. Study (Mafauzy et al., 2003) conducted in the state of 
Kelantan in North-East Peninsular Malaysia showed that hypertension is a common 
disease in this area and is associated with multiple risk factors for CVD. Subjects 
with hypertension also had a higher prevalence of T2DM (19.0%), obesity (39.4%) 
and hypercholesterolaemia (70.7%) than non-hypertensive subjects. Of the 
hypertensive subjects, 83.3% had one other risk factor for CVD, 66.7% had 2 other 
risk factors and 16.7% had more than two risk factors. Mohamad et al. (1996) 
studied prevalence of obesity and overweight in North-East Peninsular Malaysia 
and their relationship with CV risk factors and found that high prevalence of 
overweight and obesity was associated with adverse lipid and glucose metabolism 
as well as poor BP control. 
 
Prevalence of risk factors was high in the rural population of Malaysia. Global risk 
assessment conducted by Nawawi et al. (2002) showed a high-risk profile with two-
thirds being at risk, and one-third being categorised into the high-risk group. The 
prevalence of hypercholesterolaemia for total cholesterol concentrations of >= 5.2, 
>=6.5 and >=7.8 mmol/l were 67.3, 30.5 and 11.8% respectively. There was a high 
prevalence of low serum high-density lipoprotein cholesterol (13.1%), hypertension 
(30.3%), smokers (24.4%), diabetes (6.4%), IFG or glucose tolerance (13.9%), 
overweight or obesity (44.7%) and increased waist-hip ratio (WHR) (48.5%). 
 
A study (Mafauzy et al., 1999) in Kelantan studied the T2DM and associated CV 
risk factors and found that T2DM patients were more obese (38.4%) and had a 
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higher prevalence of hypertension (12.9%) and hypercholesterolaemia (71.9%).  
Subjects with IGT also had a higher prevalence of obesity (35.5%), hypertension 
(9.0%) and hypercholesterolaemia (63.0%). Ismail et al. (2000) found high 
prevalence of dyslipidaemia in T2DM patients and concluded that ethnicity and 
glycaemic control are major determinants of diabetic dyslipidaemia in Malaysia.  A 
retrospective study (n= 302) (Chiam et al., 2002) done on patients, who had 
undergone coronary artery bypass grafting (CABG) in Hospital Universiti 
Kebangsaan Malaysia, found the prevalence of T2DM (45.7%), hypertension 
(78.8%) and hyperlipidaemia (89.1%) among this cohort. The Indians had the 
highest prevalence of the three risk factors. The Chinese and the Malays most 
frequently presented with the combination of hypertension and hyperlipidaemia. 
From the studies it is established that the prevalence of obesity and overweight, 
hypertension and other risk factors and their relationship with CVD and T2DM in 
Malaysia is likely to increase in the near future with increasing affluence and 
becoming a major health problem. 
 
1.6 Diabetic vasculopathy  
Diabetes is associated with a number of microvascular (retinopathy, neuropathy, 
and nephropathy) and macrovascular (ischemic heart disease, cerebrovascular 
disease, and peripheral vascular diseases) complications (Cooper et al., 2001; Clark 
& Lee, 1995). Diabetic associated vascular complications usually involve large, 
medium and small size vessels. Macrovascular complications are the most common 
long-term problems and affect the heart and large blood vessels.  In the following 
sections, pathophysiology and pathogenesis of these factors will be discussed.  
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1.6.1 Pathophysiology of diabetic vasculopathy 
There is much physiological impairment that plausibly link diabetes with a marked 
increase in atherosclerotic vascular disease. These include endothelial dysfunction, 
smooth muscle cell dysfunction, platelet hyper-reactivity, impaired fibrinolysis 
coupled with a tendency for thrombosis and coagulation, and increased 
inflammation (Luscher et al., 2003; Creager et al., 2003). However, endothelial 
dysfunction is considered to be an important nexus of dysfunction in diabetes 
mellitus, linking each of these pathological manifestations (Beckman, 2004). 
 
1.6.1.1  Endothelial dysfunction 
Endothelial dysfunction may be functionally defined as the failure of the vascular 
endothelium to sub-serve its normal role in vasodilation and/or vascular 
homeostasis. The predominant effect of endothelium stimulation is vasodilatation. 
Other regulatory functions involve vasorelaxation, vasoconstriction, anti-platelet 
and anticoagulant effects (Kadirvelu et al., 2002). It emerges as a key component in 
the pathophysiology of diverse cardiovascular abnormalities associated with 
atherosclerosis, diabetes, hypertension, and aging (Drexler & Hornig 1999; Van der 
Loo et al., 2000). Endothelial dysfunction, present at disease onset, is the prime 
focus of atherosclerotic lesions that present throughout the course of diabetes and 
associated with late-stage adverse outcomes. Diabetes related endothelial 
dysfunction precedes morphologic and structural vascular changes (Taylor & 
Poston, 1994), which includes accelerated disappearance of capillary endothelium 
(Tooke, 1995), weakening of intercellular junctions (Rattan et al., 1997), altered 
protein synthesis and altered expression/production of adhesion glycoproteins on 
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endothelial cells (Tooke, 1995; Rattan et al., 1997; Tesfamariam et al., 1991; Paston 
& Taylor, 1995), promoting attachment of monocytes and leukocytes, as well as 
their trans-endothelial migration (Rattan et al., 1997). 
  
Endothelial dysfunction results from the imbalance between endothelium-derived 
contracting and relaxing factors. Unlike normal endothelium it produces abnormal 
response when exposed to endogenous or exogenous vasodilators. Due to 
endothelium’s strategic location between the circulating blood and vascular smooth 
muscle, it is a primary target and mediator of cardiovascular disease. Endothelium 
modulates the activity of vascular smooth muscle and therefore it regulates vascular 
tone (Furchgott & Zawadzki, 1980). Endothelial cells (EC) release humoral factors 
that control relaxation and contraction, thrombogenesis and fibrinolysis, platelet 
activation and inhibition (Kadirvelu et al., 2002). These cells provide metabolically 
active interface between blood and tissue that modulates blood flow, nutrient 
delivery and leukocyte diapedesis (Cines et al., 1998). The endothelial cells also 
synthesize important bioactive substances e.g. nitric oxide (NO), other reactive 
oxygen species, prostaglandins, endothelin and angiotensin II, which regulate blood 
vessel structure and function. Nitric oxide potently dilates vessels and mediates 
much of the endothelium's control of vascular relaxation (Verma & Anderson, 
2001). 
 
Endothelial cell damage, with loss of the vascular protective effects of NO, is likely 
the early step in atherosclerosis. Impaired endothelial-dependent vasodilatation has 
been described in patients with diabetes and the degree of impairment may correlate 
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with glycaemic control (Storey et al., 2001). This is also seen with other associated 
conditions, which lead to endothelial dysfunction e.g. hypertension, dyslipidaemia 
(Storey et al., 2001). This may be an effect of hyperglycaemia itself leading to an 
increase oxidative stress and release of mediators (e.g. cytokines) by adipocytes in 
the presence of insulin resistance (Storey et al., 2001). High glucose concentration 
is associated with increased oxidative stress (Baynes, 1991), enhanced leukocyte 
endothelial interaction (Morigi et al., 1998), and glycosylation of protein in the 
body, including lipoproteins, apolipoproteins, and clotting factors. Hyperglycaemia 
also enhances endothelial cell matrix production, which may contribute to basement 
membrane thickening (Cagliero et al., 1991). It also increases enzymes involved in 
collagen synthesis (Cagliero et al., 1991) and specifically enhances endothelial cell 
collagen IV and fibronectin synthesis (Cagliero et al., 1991).  
 
Over time, through a complex series of dehydrogenation and oxidation reactions, 
hyperglycaemia enhances the formation of advanced glycation end products (AGEs) 
(Vlassara, 1997). These end products are found in plasma, vessel wall, and tissues 
and are linked to the development of diabetic complications (Tesfamariam et al., 
1991; Johnstone et al., 1993; Parving et al., 1996; Deckert et al., 1989; Zeiher et al., 
1991; Wautier et al., 1996). These end products can also induce excessive cross-
linking of collagen and extracellular matrix proteins in the vascular wall, which in 
turn could lead to accumulation of low-density lipoprotein (LDL) particles of 
prolonged half-life. Such particles are more susceptible to oxidative modification, 
impairing endothelial cell function, stimulating inflammation and adhesion, and 
promoting vascular smooth muscle cell (SMC) changes (Lyons, 1993). 
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Atherosclerotic vascular disease is the leading cause of death in patients with 
diabetes, which mainly occurs due to endothelial dysfunction (Beckman et al., 
2002; Seligman et al., 2000). Improved metabolic control in diabetic patients, 
whatever the treatment used, is associated with near normalisation or restoration of 
normal endothelial function (Guerci et al., 2001). 
 
1.6.1.2 Smooth muscle cell dysfunction 
Progression of atherosclerotic lesion or alteration of vasculature is the characteristic 
feature of diabetic complications (Ruderman & Haudenschild, 1984). Diabetes 
accelerates these processes by stimulating the atherogenic activity of vascular SMC 
- the integral part in the development of atherosclerosis (Beckman et al., 2002). The 
process begins as a response to chronic minimal injury to the endothelium leading 
to it being dysfunctional.  
 
A dysfunctional endothelium is found to be more porous, which allows 
macrophages and LDL to penetrate to the medial layer of arteries heralding the 
formation of foam cells. The vessels are then on the way to develop atheroma. Once 
the macrophage-rich fatty streak forms, vascular SMCs in the medial layer of the 
arteries migrate into the nascent intimal lesion. Here vascular SMCs replicate and 
lay down a complex extracellular matrix, important steps in the progression to 
advanced atherosclerotic plaque (Beckman et al., 2002). These cells being the 
source of collagen, strengthen the atheroma, making it less likely to rupture and 
cause thrombosis. Lesions that have disrupted and caused fatal thrombosis tend to 
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have few vascular SMCs (Libby, 2001). Fewer vascular SMCs are also found in 
diabetic patients with advanced atherosclerotic lesions (Fukumoto et al., 1998). 
Hyperglycaemic lipid modifications of LDL regulate the increased migration and 
cell death of vascular SMCs in atherosclerotic lesions. Low-density lipoprotein that 
has undergone non-enzymatic glycation induces vascular SMC migration in vitro, 
while oxidized glycated LDL can induce cell death of vascular SMCs (Taguchi et 
al., 2000). High glucose concentrations promote necrotic cell death through 
hydrogen-peroxide (H2O2) formation, which may participate in the development of 
diabetic vasculopathy (Chaturvedi et al., 2001). Thus, diabetes alters vascular 
smooth muscle function in ways that promote atherosclerotic lesion formation, 
plaque instability and clinical events. 
 
1.6.1.3 Impaired platelet function 
Platelet aggregation and adhesion are characteristically highlighted in people with 
diabetes (Walsh et al., 1995; Stein et al., 1995; Winocour et al., 1990; Davi et al., 
1990). Diabetes increases intrinsic platelet activation and decrease endogenous 
inhibitors of platelet activity (Beckman et al., 2002). Platelets from patients with 
diabetes exhibit enhanced platelet aggregation activity in the early disease state that 
may precede the development of CVD (Vlassara, 1997; Parving et al., 1996; 
Chaturvedi et al., 2001; Walsh et al., 1995; Stein et al., 1995; Winocour et al., 
1990; Davi et al., 1990). Numerous biochemical abnormalities have been found that 
correlate with platelet hyper-reactivity. Vascular diseases are characterised by 
abnormal vascular homeostasis manifest as impaired vasodilation and the promotion 
of platelet aggregation. Abnormalities in platelet function may exacerbate the 
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progression of atherosclerosis and the consequences of plaque rupture. The 
functional abnormalities appear to be related to exaggerated elevations in platelet 
intracellular calcium mobilization (Davi et al., 1990; Standley et al., 1993; Levy et 
al., 1994; Fakuda et al., 1997). Intra-platelet glucose concentration reflects the 
extracellular concentration, but glucose entry into the platelet does not depend on 
insulin (Vinik et al., 2001). Platelets can modulate vascular function and participate 
significantly in thrombus formation. Platelets from people with diabetes have 
reduced membrane fluidity that is thought to be related to membrane cholesterol-to-
phospholipid ratio (Winocour et al., 1990). Another process that likely contributes 
to enhanced platelet aggregation is an increase in glycation of platelet membrane 
proteins (Sampretro et al., 1986). 
 
Dyslipidaemia contributes directly and indirectly to platelet aggregation (Sowers & 
Epstein, 1999). Besides, platelet-derived growth factor (PDGF) stimulates migration 
and proliferation of SMC and extracellular matrix (ECM) production. These 
contribute to the formation of subendothelial ‘fibrointimal’ lesion and possibly the 
formation of the outer capsule of predominantly fatty lesions, which induce the 
development of atherosclerosis (Myllärniemi et al., 1997). Increased production of 
PDGF by the vascular endothelium in response to high glucose concentration and 
angiotensin II has been reported in vitro (Okuda et al., 1996). The PDGF-β-receptor 
expression has also been demonstrated to be stimulated by hyperglycaemia via 
protein kinase C (PKC) activation in vascular SMCs, decreased production of 
platelet-derived NO and increased formation of superoxide (O-2). This suggests a 
possible involvement of PDGF in the development of diabetic vasculopathy (Assert 
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et al., 2001; Inaba et al., 1996). These abnormalities may result from decreased 
endothelial production of the antiaggregants NO and prostacyclin, decreased 
antioxidant levels, increased production of fibrinogen and platelet activators such as 
thrombin and von Willebrand factor (vWF) (Vinik et al., 2001). Moreover, diabetic 
patients have increased expression of activation-dependent adhesion molecules e.g., 
glycoprotein Ib (GpIb-IIIa) and P-selectin (Vinik et al., 2001). 
 
Among diabetic individuals, increased platelet aggregation and adhesiveness (Jokl 
& Colwell, 1997; Halushka et al., 1981; Mayfield et al., 1985; Watala et al., 1999; 
Martina et al., 1998; Trovati et al., 1997; Sarji et al., 1979; Tschoepe et al., 1997) 
are caused by reduced membrane fluidity, increased arachidonic acid metabolism, 
increased thromboxane A2 (TXA2) synthesis, and altered Ca2+ and Mg2+ 
homeostasis (increased intracellular Ca2+ mobilization and decreased intracellular 
Mg2+) (Li et al., 2001). Nitric oxide is a principal mediator of vascular homeostasis. 
These features of abnormal vascular homeostasis are due to impaired bioactivity of 
endothelium- and platelet-derived NO. Disordered calcium regulation may 
contribute significantly to abnormal activity; since intra-platelet calcium regulates 
platelet shape change, secretion, aggregation and thromboxane formation (Vinik et 
al., 2001). 
 
1.6.1.4 Coagulation abnormalities in diabetes  
Diabetes also brings about some changes in coagulation of blood. A procoagulant 
state has been demonstrated in people having diabetes (García et al., 1987; Ford et 
al., 1991; Carmassi et al., 1992). There is increase in the number of coagulation 
